Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIANO: PLX3397 in Advanced Acral and Mucosal Melanoma
NCT02071940Phase 2Completed
- Sponsor
- The Christie
- Start
- Oct 2015
- Primary completion
- Mar 2021
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of pexidartinib in acral lentiginous melanoma (ALM), mucosal melanoma (MM), sponsored by The Christie. Started Oct 2015; status: completed.
02
Drugs
pexidartinib
03
Conditions
acral lentiginous melanoma (ALM)mucosal melanoma (MM)
Beyond the preview
Go deeper on NCT02071940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02071940.